Either way, the effectiveness of PRMT5 and MAT2A inhibitors depends on the accumulation of MTA in cancer cells with MTAP gene deletion (Figure 1B) [3,4,5,6,7,9,10,12]. This evidence concerns the gene MTAP and cancer.